Pliant Therapeutics Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Pliant Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.00 $ to 1.90 $ · Last price: 1.10 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Pliant Therapeutics Inc PLRX | 0.1 | – | -2.5 | – | – | -100.0 | -22.6 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 57.0 | 21.8 | 5.1 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | – | -18 | -21 | -25.67 | -17 | 3 | 7 |
| 2018 | 0 | -31 | -30 | -1.83 | -28 | -1 | 67 |
| 2019 | 57 | -1 | -1 | -0.02 | -3 | 0 | 119 |
| 2020 | 42 | -42 | -40 | -1.12 | -37 | 283 | 296 |
| 2021 | 8 | -20 | -18 | -0.50 | -75 | 199 | 221 |
| 2022 | 10 | -127 | -123 | -2.94 | -95 | 313 | 351 |
| 2023 | 2 | -184 | -161 | -2.75 | -116 | 474 | 512 |
| 2024 | 0 | -228 | -210 | -3.47 | -156 | 304 | 397 |
| 2025 | 0 | -150 | -149 | -2.43 | -128 | 181 | 225 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.80 | – | 2 | -53.10 | -2,190.80 | -48 | -48 |
| 2025: Q1 | -0.91 | – | 0 | – | – | -49 | -49 |
| 2025: Q2 | -0.70 | – | 0 | – | – | -41 | -41 |
| 2025: Q3 | -0.42 | – | 0 | – | – | -21 | -21 |
| 2025: Q4 | -0.38 | – | 0 | -100.00 | – | -18 | -18 |
| 2026: Q1 | -0.32 | – | 0 | – | – | -19 | -19 |
| 2026: Q2 | -0.36 | 48.60 | – | – | – | -13 | -13 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Value & GARP
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.43 | -1.47 – -1.41 | 0 | 40.4% | 3 |
| 12/31/2027 | -1.28 | -1.47 – -0.94 | 0 | 10.4% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
In den ausgewerteten SEC-Berichten von Pliant Therapeutics (4 Quartalsberichte 10-Q und 2 Jahresberichte 10-K) findet sich kein wesentlicher KI-Bezug: Das Geschäft ist die klinische Entwicklung integrin-basierter Wirkstoffe (Lead PLN-101095, ein oraler Integrin-Hemmer gegen solide Tumoren); KI ist weder Umsatzquelle noch belegter operativer Baustein noch ein konkret aufs eigene Modell bezogenes Geschäftsrisiko. Die Wirkstoff-Entdeckungsplattform wird als »proprietäre Bibliothek von über 15.000 Integrin-Bindemolekülen« beschrieben, ohne KI oder maschinelles Lernen zu erwähnen. Die einzige Nennung von »artificial intelligence« ist eine generische regulatorische Randbemerkung, dass die US-Arzneimittelbehörde FDA neue Richtlinien zum KI-Einsatz bei der Prüfung von Zulassungsanträgen angekündigt habe — kein Bezug zu Pliants eigenem Geschäftsmodell.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-K 2026-03-11 · 10-K 2025-03-03 · 10-Q 2026-05-11 · 10-Q 2025-11-06 · 10-Q 2025-08-07 · 10-Q 2025-05-08
Rated on July 9, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0%
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year 13.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 162 m net cash
- Operating cash flow covers the profits of the last three years 121 m
- Return on capital at 15% or higher, or up versus two years ago -71.9%
- Insiders hold at least 10% or are net buyers 2.4%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -82.4%
- ROCE > 15% -71.9%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Pliant Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entdeckung und Entwicklung integrinbasierter Therapeutika zur Behandlung solider Tumore.
- Employees
- 49
- Headquarters
- South San Francisco, CA
- Address
- 331 Oyster Point Boulevard, 94080 South San Francisco, United States
- Phone
- 650 481 6770
- Website
- pliantrx.com
- IPO Date
- 06/03/2020
- ISIN
- US7291391057
Management
| Name | Title | Birth Year |
|---|---|---|
| Bernard Coulie M.B.A., M.D., Ph.D. | President, CEO & Director | 1966 |
| Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer | 1977 |
| Minnie Kuo | Chief Operating Officer | 1981 |
| Rik Derynck Ph.D. | Scientific Founder & Member of Scientific Advisory Board | – |
| Dean Sheppard M.D. | Scientific Founder & Member of Scientific Advisory Board | – |
| Lily Cheung | Chief Human Resources Officer | 1973 |
| Tim Machajewski Ph.D. | Senior VP & Head of Research | – |
| Scott Peters | Senior Vice President of Finance | – |
| Daniel Park | Senior Vice President of Development Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/11/2026 PLIANT THERAPEUTICS, INC. (PLRX): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/13/2026 PLIANT THERAPEUTICS, INC. (PLRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.